Oral Gut Liver Axis in Cirrhosis
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
This will be a prospective study of cirrhotics and healthy controls comparing their oral microbiota, endotoxemia and systemic inflammation at baseline and at 10 and 30 days after clinically indicated systematic oral cleansing and interventions as well as 3-month hospitalizations post-cleaning.
The investigators will recruit cirrhotic subjects and age- matched healthy controls from the hepatology clinics. Subjects will be informed regarding the study and will give the investigators a written informed consent.
After informed consent and evaluation of eligibility, subjects will be asked to complete an oral health questionnaire and sample collection during the recruitment visit. Patients will then be scheduled for a dental exam during a separate screening visit up to 7 days after this recruitment visit at the Dental Clinics.
At this time patients will undergo cognitive testing consisting of a validated cognitive battery of PHES (psychometric hepatic encephalopathy score) and EncephalApp stroop. In addition, they will undergo Sickness Impact Profile (a quality of life questionnaire).
During dental exam which will be done during screening visit, the subject will undergo comprehensive oral evaluation which will include dental xrays (as needed) which are part of the study, periodontal examination (determination of pocket depth, clinical attachment levels, bleeding on probing, plaque index) and recording of caries and oral soft tissue lesions. Dental cleaning is part of the study protocol and not intended to fully treat the patient's periodontal and dental diseases. Therefore no follow-up dental visits will be scheduled in the dental clinics after completion of dental cleansing.
The patients who do not qualify for the study will be informed of the findings by the dental professionals and subsequently the patients need to make arrangements for their dental treatment needs.
The study will include cirrhotic patients with/without hepatic encephalopathy. Subjects will then be scheduled for dental cleaning which could occur over 1 or 2 visits as determined during the screening exam.
Before the initiation of oral therapy, plaque and gingival crevicular samples will be collected for microbiota. The subjects will receive deep dental cleanings (scaling and root planing) and oral hygiene instructions as per clinical indication.
Subjects will then be followed at day 10 for clinical exam and day 30 at which point stool, saliva and blood samples for the similar analyses as before will be collected. There will be no more dental examinations after the initial assessment and treatment. We will repeat the cognitive testing at day 30 using alternate forms of the same cognitive tests and also repeat quality of life testing at day 30 .
The investigators will also follow them for up to 3 months post-cleaning for hospitalizations using active chart review and follow-up
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Virginia
-
Richmond, Virginia, United States, 23298
- Virginia Commonwealth University
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion criteria:
Cirrhotic subjects:
- Age 21-75 years
- Able to give informed consent
- Cirrhosis diagnosed using biopsy or suggestive radiological features or endoscopic evidence of varices in a subject with chronic liver disease
Healthy controls:
- Age 21-75 years
- Able to give informed consent
- Without chronic diseases
Exclusion Criteria:
Exclusions for all subjects (will be done at the screening visit at both clinics)
- Current use of absorbable antibiotics (use of antibiotics within 4 weeks)
- Diagnosed with severe chronic or aggressive forms of periodontitis based on American Academy of Periodontology Classification (5)
- Presence of more than 2 severe cavitated caries lesions
- Presence of oral soft-tissue lesions such as ulcers
- Presence of abscesses
- Unclear diagnosis of cirrhosis (for cirrhotics)
- Edentulous or less than 20 natural teeth
- Smoking, oral tobacco and alcohol abuse within 3 months
- Prisoners
- Pregnant women
- INR(international normalized ratio) >1.5
- Platelet count <50,000
- Diagnosed bleeding disorders
- Patients on anti-coagulation
- Patients who will otherwise be eligible for prophylactic antibiotics before dental cleaning
- Last dental cleaning within 3 months of study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Dental cleaning
Patients with cirrhosis and healthy controls will undergo dental examination and subsequent dental cleaning if necessary.
|
This is standard of care dental cleaning as is guided by the initial dental evaluation
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in serum endotoxin
Time Frame: 30 days
|
Relative change in serum endotoxin levels using LAL (limulus amebocyte lysate) assay will be measured before/after cleaning and between groups
|
30 days
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in performance on two batteries of Cognitive function
Time Frame: 30 days
|
Relative change in PHES battery (total standard deviations above normal performance)and EncephalApp Stroop values (seconds taken) will be measured before/after cleaning and between groups
|
30 days
|
|
Change in systemic inflammatory cytokines in the blood
Time Frame: 30 days
|
Relative change in pg/ml of serum IL-6 (interleukin), IL-1b (interleukin) using ELISA assays will be measured before/after cleaning and between groups
|
30 days
|
|
All-cause Hospitalizations
Time Frame: 3 months
|
All-cause, liver-related and elective hospitalizations at 3 months will be studied and compared between groups
|
3 months
|
|
Change in microbiota composition in the saliva and stool
Time Frame: 30 days
|
Relative change in microbial composition using 16SrRNA multi-tagged sequencing in stool and saliva will be measured before/after cleaning and between groups
|
30 days
|
|
MELD (model for end-stage liver disease) score change in the cirrhosis group
Time Frame: 30 days
|
Relative change in MELD score will be analyzed in cirrhotic patients before/after cleaning
|
30 days
|
|
Quality of life changes
Time Frame: 30 days
|
Changes in quality of life using Sickness Impact Profile will be measured
|
30 days
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Jasmohan Bajaj, MD, VCU Medical Center
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- HM20006081
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Periodontitis
-
NCT07293962RecruitingPeriodontitis | Periodontitis Chronic Generalized Moderate | Periodontitis (Stage 3) | Periodontitis, Adult | Periodontitis Chronic Generalized Severe | Periodontitis, Chronic | Periodontitis Stage II | Periodontitis Chronic Localized Slight | Periodontitis Stage III
-
NCT07505251Not yet recruitingPeriodontitis Stage II | Periodontitis Stage III | Periodontitis Stage IV
-
NCT07590089CompletedPeriodontitis | Periodontitis Stage I | Periodontitis Stage II | Periodontitis Stage III
-
NCT07599657RecruitingPeriodontitis | Periodontitis Stage II | Periodontitis Stage III
-
NCT07517991CompletedPeriodontitis | Periodontitis Stage I | Periodontitis Stage II
-
NCT06675578Not yet recruitingStage IV Periodontitis | Advanced Periodontitis | Stage III Periodontitis
-
NCT02423304UnknownGeneralized Adult Periodontitis
-
NCT07351682Not yet recruiting
-
NCT07387809Active, not recruiting
-
NCT07249450Completed
Clinical Trials on Dental Cleaning
-
NCT02619903CompletedPulmonary Disease, Chronic Obstructive | Dental Plaque | COPD Exacerbation
-
NCT07535008RecruitingAcute Graft Versus Host Disease | Chronic Graft Versus Host Disease | Hematopoietic and Lymphatic System Neoplasm
-
NCT02914743CompletedPeriodontal Disease | Type II Diabetes
-
NCT03087240UnknownRheumatoid Arthritis | Periodontitis | Gingivitis | Dental Prophylaxis
-
NCT07478653Not yet recruitingObesity | Dental Care for Children
-
NCT05335239CompletedAging | Dental Caries of Root Surface
-
NCT06052150Active, not recruitingPeriodontal Diseases | Cirrhosis
-
NCT05721781RecruitingBacteremia | Infective Endocarditis
-
NCT07591844Not yet recruitingPeriodontitis | Stable Angina Pectoris
-
NCT07412795Not yet recruitingPeriodontitis | Stable Angina